Long-term safety and efficacy of eslicarbazepine acetate in patients with focal seizures: results of the 1-year ESLIBASE retrospective study
V Villanueva, JM Serratosa, E Guillamón, M Garcés… - Epilepsy research, 2014 - Elsevier
Background Eslicarbazepine acetate (ESL) is a new antiepileptic drug (AED) licensed as
adjunctive therapy in adults with partial-onset or focal seizures. Objective To evaluate in a …
adjunctive therapy in adults with partial-onset or focal seizures. Objective To evaluate in a …
Efficacy and safety of eslicarbazepine acetate monotherapy for partial-onset seizures: experience from a multicenter, observational study
R Toledano, CE Jovel, A Jiménez-Huete, PG Bayarri… - Epilepsy & Behavior, 2017 - Elsevier
Abstract Eslicarbazepine acetate (ESL, Aptiom™) is a once-daily anticonvulsant, approved
as adjunctive treatment of partial-onset seizures (POS). Historical-controlled trials …
as adjunctive treatment of partial-onset seizures (POS). Historical-controlled trials …
[PDF][PDF] Eslicarbazepine acetate
L Almeida, M Bialer, P Soares-da-Silva - The treatment of epilepsy, 2009 - academia.edu
Eslicarbazepine acetate (BIA 2-093) is a novel voltage-gated sodium channel blocker that
was identified as a promising candidate for clinical development through a drug discovery …
was identified as a promising candidate for clinical development through a drug discovery …
Efficacy and safety of eslicarbazepine acetate versus controlled‐release carbamazepine monotherapy in newly diagnosed epilepsy: a phase III double‐blind …
Objective We assessed the efficacy and safety of once‐daily eslicarbazepine acetate in
comparison with twice‐daily (BID) controlled‐release carbamazepine (carbamazepine‐CR) …
comparison with twice‐daily (BID) controlled‐release carbamazepine (carbamazepine‐CR) …
[HTML][HTML] Efficacy and safety of conversion to monotherapy with eslicarbazepine acetate in adults with uncontrolled partial-onset seizures: a historical-control phase III …
MP Jacobson, L Pazdera, P Bhatia, T Grinnell… - BMC neurology, 2015 - Springer
Abstract Background Eslicarbazepine acetate (ESL, Aptiom®) is a once-daily (QD)
anticonvulsant, approved as adjunctive treatment of partial-onset seizures (POS). It is …
anticonvulsant, approved as adjunctive treatment of partial-onset seizures (POS). It is …
Eslicarbazepine acetate in clinical practice. Efficacy and safety results
PJ Serrano-Castro, M Payán-Ortiz… - Revista de …, 2013 - europepmc.org
INTRODUCTION. Eslicarbazepine acetate (ESL) is a new antiepileptic drug (AED) licensed
in Spain in February 2011 as an adjunctive therapy in adults with partial seizures with or …
in Spain in February 2011 as an adjunctive therapy in adults with partial seizures with or …
Eslicarbazepine acetate
PL McCormack, DM Robinson - CNS drugs, 2009 - Springer
Abstract▴ Eslicarbazepine acetate, a prodrug of eslicarbazepine (S-licarbazepine), is a
novel, voltage-gated sodium channel antagonist under development for the adjunctive …
novel, voltage-gated sodium channel antagonist under development for the adjunctive …
Pharmacokinetics and drug interactions of eslicarbazepine acetate
M Bialer, P Soares‐da‐Silva - Epilepsia, 2012 - Wiley Online Library
Eslicarbazepine acetate (ESL) is a novel once‐daily antiepileptic drug (AED) approved in
Europe since 2009 that was found to be efficacious and well tolerated in a phase III clinical …
Europe since 2009 that was found to be efficacious and well tolerated in a phase III clinical …
Two-year follow-up with eslicarbazepine acetate: a consecutive, retrospective, observational study
FD Correia, J Freitas, R Magalhães, J Lopes… - Epilepsy research, 2014 - Elsevier
Purpose Eslicarbazepine acetate (ESL) is a new generation voltage-gated sodium channel
blocker. It has completed one phase II clinical trial and three phase III clinical trials, two of …
blocker. It has completed one phase II clinical trial and three phase III clinical trials, two of …
Efficacy and safety of conversion to monotherapy with eslicarbazepine acetate in adults with uncontrolled partial‐onset seizures: a randomized historical‐control …
MR Sperling, J Harvey, T Grinnell, H Cheng, D Blum… - …, 2015 - Wiley Online Library
Objective To assess the efficacy and safety of eslicarbazepine acetate (ESL) as
monotherapy in North American patients with partial‐onset seizures (POS). Methods This …
monotherapy in North American patients with partial‐onset seizures (POS). Methods This …